Patients with FGF23-related hypophosphatemic rickets/osteomalacia do not present with left ventricular hypertrophy
Yuichi Takashi(Fukuoka University), Seiji Fukumoto(Tokushima Hospital), Nobuaki Ito(University of Tokyo Hospital), Yuka Kinoshita(University of Tokyo Hospital), Manabu Taguchi(The University of Tokyo), Michiko Hori(University of Tokyo Hospital)
Cited by 67
Related Papers
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period
|Calcified Tissue International|2019|160
X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment
|Endocrine Reviews|2018|148
Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation
|Proceedings of the National Academy of Sciences|2019|147
Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients
|Kidney International|2005|132
Runx1 and Runx2 cooperate during sternal morphogenesis
|Development|2010|94